stroke risk and complication rate likely reflects 4 important factors: careful patient selection, excellent surgical technique, meticulous intraoperative and perioperative management, and attentive patient follow-up. Moreover, although this study does not prove that a combined indirect and direct revascularization procedure is superior to other approaches, the low rate of recurrent stroke and hemorrhage is compelling. Moving forward, prospective cohort and randomized trials are needed to further define best evidence-based practice. Future studies should also assess cognitive function and quality of life in greater depth. Adult moyamoya disease is an important cause of stroke and cognitive decline and a critical area for continued research.
Toxin-Secreting Implantable Therapeutic Stem Cells P seudomonas exotoxin (PE) exerts cellular toxicity by inactivating elongation factor-2 and blocking protein synthesis. Conjugation of PE to ligands directed at cancer cell-specific antigens has clinical success in the treatment of some leukemias and lymphomas and limited success in solid tumors. One of the more recent therapeutic targets to gain attention in glioblastoma research has been the interleukin-13 (IL13) receptor a2, a variant overexpressed in glioblastoma cells but not in normal brain. There has been strong preclinical evidence for targeting this receptor to selectively deliver PE to glioblastoma cells. This strategy has yet to yield positive clinical results, as evidenced by the phase III PRECISE trial, which compared convectionenhanced delivery of an IL13-PE conjugate to camustine implants (Gliadel wafers) in patients with first recurrence of glioblastoma. 1 The lack of improved outcomes with the IL13-PE-conjugated drug compared with Gliadel wafers was partly attributed to poor drug delivery from suboptimal catheter positioning in more than half of the subjects. 2 Another highly relevant factor may be the short half-life of the drug and the short administration period of only 4 days.
Conceptually, Gliadel has the advantage of implantation directly at the margins of resection with carmustine diffusion into the surrounding parenchyma over time as the polymer degrades. What if this concept could be used to deliver a highly effective and stable biological agent? Stuckey and colleagues 3 report engineering human neural stem cells to stably express IL13-PE. They first generated PE-resistant human neural stem cells by inducing specific mutations in the elongation factor-2 gene. They then selected and engineered the PE-resistant clones to stably express IL13-PE. Multiple established glioblastoma cell lines and 5 patient-derived glioblastoma cell lines were cocultured with the toxin-secreting stem cells. The toxicity of the engineered cells was highly correlated with the IL13 receptor a2 expression level in the glioblastoma cell lines. Additionally, the researchers provide strong evidence that inhibition of protein synthesis is the molecular mechanism mediating the IL13-PE stem cell toxicity (Figure) .
The IL13-PE-secreting neural stem cells were encapsulated in a synthetic extracellular matrix and tested in a mouse tumor resection model. One week after glioblastoma cell implantation, tumors were surgically debulked, and the resection cavity was filled with the IL13-PEsecreting stem cells encapsulated in a synthetic extracellular matrix from which they could diffuse freely. Tumor progression was tracked with bioluminescence imaging. This treatment was compared with injection of IL13-PE in conditioned media and with resection alone. A significant survival benefit was observed. Mice receiving the toxin-secreting stem cells embedded within the matrix demonstrated a median survival of 79 days vs 48 and 26 days in the IL13-PE injection and resection-only groups, respectively. Additionally, at 21 days after resection, no tumor masses developed in the encapsulated toxin-secreting stem cell group, whereas tumors of various sizes were found in the other groups. The tumor imaging results imply some transient retention of the toxinsecreting stem cells. Unfortunately, the investigators were unable to detect viable stem cells in the resection cavity after 72 hours by bioluminescence.
Many potential agents against glioblastoma will be challenged by drug stability and poor blood-brain barrier permeability. Using neural stem cells to secrete tailored tumorspecific toxins or other biological agents within the resection cavity in direct contact with residual tumor may help overcome these obstacles. Although there are significant barriers to the clinical use of either autologous or nonautologous neural stem cells for the treatment of glioblastoma, Stuckey and colleagues present important in vivo evidence of the feasibility of engineering neural stem cells to secrete targeted cytotoxins that affect tumor progression.
